Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.72 Insider Own0.30% Shs Outstand38.32M Perf Week13.44%
Market Cap1.23B Forward P/E- EPS next Y-2.72 Insider Trans3.52% Shs Float30.83M Perf Month-20.08%
Income-140.80M PEG- EPS next Q-1.17 Inst Own50.40% Short Float14.66% Perf Quarter7.03%
Sales- P/S- EPS this Y-25.30% Inst Trans3.60% Short Ratio4.23 Perf Half Y-11.07%
Book/sh0.38 P/B83.29 EPS next Y39.20% ROA-129.10% Target Price81.21 Perf Year-42.84%
Cash/sh2.19 P/C14.48 EPS next 5Y- ROE-389.70% 52W Range19.38 - 74.10 Perf YTD-16.23%
Dividend- P/FCF- EPS past 5Y-19.50% ROI- 52W High-60.64% Beta2.44
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low50.51% ATR3.51
Employees108 Current Ratio3.50 Sales Q/Q- Oper. Margin- RSI (14)44.37 Volatility9.98% 10.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.30% Profit Margin- Rel Volume0.73 Prev Close31.65
ShortableYes LT Debt/Eq3.35 EarningsMay 02 BMO Payout- Avg Volume1.07M Price29.17
Recom1.80 SMA20-6.44% SMA50-17.16% SMA200-11.45% Volume268,196 Change-7.84%
Aug-10-21Downgrade Morgan Stanley Overweight → Equal-Weight $105 → $34
Jun-10-21Initiated Berenberg Buy $112
Jan-08-21Initiated Jefferies Buy $129
Dec-16-20Initiated Mizuho Buy $120
Sep-29-20Initiated BofA Securities Underperform $66
Sep-10-20Initiated Morgan Stanley Overweight $102
Apr-28-20Reiterated H.C. Wainwright Buy $200 → $210
Apr-14-20Initiated Cowen Outperform $95
Dec-30-19Reiterated H.C. Wainwright Buy $170 → $200
Dec-17-19Reiterated H.C. Wainwright Buy $30 → $170
Dec-16-19Reiterated Guggenheim Buy $65 → $158
Oct-16-19Initiated Guggenheim Buy $48
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
May-18-22 11:23AM  
May-16-22 08:30AM  
May-14-22 06:15AM  
May-13-22 04:00PM  
May-11-22 07:59AM  
May-09-22 05:46PM  
May-06-22 12:17PM  
May-03-22 10:49AM  
May-02-22 03:00PM  
Apr-27-22 12:44PM  
Apr-25-22 04:07PM  
Apr-22-22 04:00PM  
Apr-20-22 10:49AM  
Apr-19-22 04:13PM  
Apr-07-22 12:05PM  
Apr-01-22 09:00PM  
Mar-30-22 01:29PM  
Mar-29-22 06:19PM  
Mar-28-22 05:36PM  
Mar-11-22 07:00AM  
Mar-06-22 07:04AM  
Mar-03-22 11:03AM  
Mar-02-22 11:16AM  
Mar-01-22 02:13PM  
Feb-28-22 10:00AM  
Feb-18-22 11:50AM  
Feb-15-22 07:00AM  
Feb-11-22 07:00AM  
Feb-10-22 10:00AM  
Feb-09-22 12:01PM  
Feb-08-22 09:09AM  
Feb-04-22 12:00PM  
Jan-28-22 03:36PM  
Jan-26-22 10:00AM  
Jan-18-22 06:55PM  
Jan-17-22 10:00AM  
Jan-09-22 10:30AM  
Jan-07-22 08:32AM  
Dec-26-21 09:31AM  
Dec-16-21 04:38PM  
Dec-15-21 12:38AM  
Dec-13-21 04:38PM  
Dec-07-21 10:00AM  
Dec-03-21 08:36AM  
Dec-02-21 06:15PM  
Nov-25-21 05:57AM  
Nov-24-21 06:25AM  
Nov-10-21 10:18AM  
Nov-09-21 10:04AM  
Nov-08-21 05:30PM  
Oct-20-21 07:00AM  
Oct-18-21 07:00AM  
Oct-17-21 06:21AM  
Oct-15-21 10:00AM  
Oct-14-21 10:30AM  
Oct-06-21 10:45AM  
Sep-29-21 10:03PM  
Sep-25-21 07:00AM  
Sep-24-21 01:45PM  
Sep-23-21 06:43AM  
Sep-17-21 10:05AM  
Sep-16-21 07:00AM  
Sep-15-21 10:26AM  
Sep-14-21 07:00AM  
Sep-08-21 02:15PM  
Sep-07-21 05:00PM  
Sep-05-21 09:55AM  
Sep-02-21 06:02AM  
Sep-01-21 02:42PM  
Aug-27-21 10:40AM  
Aug-24-21 11:37AM  
Aug-23-21 12:15PM  
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorMar 15Option Exercise1.303,4964,5457,596Mar 17 07:05 AM
JEFFS ROGERDirectorNov 19Buy37.303,950147,350120,756Nov 23 07:30 AM
Pizzie NickCHIEF FINANCIAL OFFICERNov 18Buy34.9742814,968201Nov 22 07:31 AM
Pizzie NickCHIEF FINANCIAL OFFICERNov 18Buy35.5052718,70841,789Nov 22 07:31 AM
Coleman MarkDirectorNov 18Buy35.091,43050,181422,428Nov 22 07:30 AM
Saad Mark EDirectorNov 17Buy34.4130010,324100Nov 19 07:30 AM
Saad Mark EDirectorNov 17Buy34.533,000103,59710,002Nov 19 07:30 AM